A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis - Zhang, Qing; Wei, Ang; Ma, Hong-Hao; Zhang, Li; Lian, Hong-Yun; Wang, Dong; Zhao, Yun-Ze; Cui, Lei; Li, Wei-Jing; Yang, Ying; Wang, Tian-You; Li, Zhi-Gang; et al. (Haematologica (Roma), 2021)
Keywords: Hemophagocytic lymphohistiocytosis (HLH); JAK-STATs inhibitor; ruxolitinib; front-line therapy